Daniel Emina
Psychiatry · Costa Mesa, CANPI 1861633786
Payments from drug & device makers
Across 104 payments — averaging $29.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tempus AI, Inc$750
- AbbVie$436
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$362
- Lundbeck LLC$241
- Corium, LLC$236
- Johnson & Johnson$155
- plus $907 from 15 others
What the payments were for
- Consulting fees$75024%
- Food & beverage$2,33576%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$114
How this compares
$3,086 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 26 | $55,203 |
| RexultiBrexpiprazole | 22 | $31,322 |
| TrintellixVortioxetine Hydrobromide | 32 | $17,012 |
| Atomoxetine Hcl | 30 | $2,991 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 33 | $2,669 |
| Lurasidone Hcl | 14 | $2,234 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $995 |
| Pregabalin | 26 | $833 |
| Armour ThyroidThyroid,pork | 20 | $781 |
| Quetiapine Fumarate | 30 | $652 |
| Fluoxetine Hcl | 38 | $597 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $488 |
| Bupropion Hcl SrBupropion Hcl | 23 | $483 |
| Olanzapine | 21 | $452 |
| Modafinil | 13 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $85 | $55,20326 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $121 | $31,32222 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $75 | $17,01232 claims |
| AbbVieArmour Thyroid | $436 | $78120 claims |
| Lilly USA, LLCOlanzapine | $23 | $45221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Costa Mesa
- Diane HighumCosta Mesa$8.8M
- Robert BotaCosta Mesa$4.2M
- Alejandro AlvaCosta Mesa$1.5M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.